Mode
Text Size
Log in / Sign up
N/A N=11 Treatment

Healing Rate of Leg Wounds Treated With Contact and Noncontact Ultrasound: The VIP Ultrasound Protocol

Chronic Ulcer of Lower Extremity

Enrolled (actual)
11
Serious AEs
0.0%
Results posted
Jan 2022
Primary outcome: Primary: Total Wound Area — 7.93125; 7.93125; 1.3275; 8.80875 Squared centimiters

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Contact Ultrasound Therapy (Device); Noncontact Ultrasound Therapy (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Texas Health Resources
Primary completion
Aug 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Total Wound Area
7.93125; 7.93125; 1.3275; 8.80875
SECONDARY
Total Wound Volume
9.561; 2.67475; 0.394; 2.086
SECONDARY
Wounds With Slough/Eschar Reduction on Visit 2 and Wounds With Slough/Eschar Reduction at Last Visit
4; 8; 4; 7

Summary

Wound healing rate is higher when contact ultrasound therapy is followed by noncontact ultrasound therapy on sub-acute and chronic lower extremity ulcers of various etiologies requiring selective debridement, as compared to either Sonoca-180 or MIST Therapy alone.

Eligibility Criteria

Inclusion Criteria

  • Patient is referred to Physical Therapy for contact ultrasound (which is included in the VIP protocol);
  • Lower extremity (including foot) wound(s) of any etiology;
  • Wound(s) presenting with slough, necrotic tissue, and/or non-viable tissue requiring debridement;
  • Wound is present for 4 weeks or longer at the start of ultrasonic therapy;
  • Insurance approval is obtained for Contact and Noncontact ultrasound treatments, in the ambulatory setting;
  • Patient is 18 years of age or older;
  • Female patient attesting not to be pregnant;
  • Not undergoing Vacuum Assisted Closure (VAC) therapy.

Exclusion Criteria

  • Patient is referred to Physical Therapy for noncontact ultrasound only;
  • Wound(s) not on lower extremity;
  • Clean wound(s) that do not require debridement;
  • Wound onset less than 4 weeks prior to the start of ultrasonic therapy;
  • Malignancies on the treatment area;
  • Patients in the ambulatory setting whose insurance did not approve them for both contact and noncontact ultrasound therapy;
  • Patient is under 18 years of age;
  • Female patient attesting to be pregnant;
  • VAC Therapy.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02045303). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search